Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal

CARDINAL HEALTH INC

Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.
Pharm & Specialty segment profit $531M (+7%); Global Medical Products profit $18M vs $11M.
FY2025 non-GAAP EPS guidance raised to $7.85-$8.00 from $7.75-$7.90; segment profit growth revised.
Completed acquisition of 73% of GI Alliance (gastroenterology MSO) and ION acquisition in Dec.
Started commercial-scale production of actinium-225 for theranostics; new distribution center underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.